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Lineage
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1Department of Chemistry and Biochemistry, Swarthmore College, Swarthmore, PA, United States, 2Department of Biology,
Swarthmore College, Swarthmore, PA, United States
Understanding affinity maturation of antibodies that can target many variants of HIV-1 is
important for vaccine development. While the antigen-binding site of antibodies is known
to mutate throughout the co-evolution of antibodies and viruses in infected individuals,
the roles of the mutations in the antibody framework region are not well understood.
Throughout affinity maturation, the CH103 broadly neutralizing antibody lineage, from
an individual designated CH505, altered the orientation of one of its antibody variable
domains. The change in orientation was a response to insertions in the variable loop 5 (V5)
of the HIV envelope. In this study, we generated CH103 lineage antibody variants in which
residues in the variable domain interfaceweremutated, andmeasured the binding to both
autologous and heterologous HIV-1 envelopes. Our data show that very few mutations in
an early intermediate antibody of the lineage can improve binding toward both autologous
and heterologous HIV-1 envelopes. We also crystallized an antibody mutant to show
that framework mutations alone can result in a shift in relative orientations of the variable
domains. Taken together, our results demonstrate the functional importance of residues
located outside the antigen-binding site in affinity maturation.
Keywords: human immunodeficiency virus (HIV), antibody, evolution, crystal structure, somatic
hypermutation, framework
INTRODUCTION
A well-recognized aspect of antibody affinity maturation is the somatic hypermutation (SHM) of
the antigen binding regions, i.e., the complementarity determining regions, or CDRs (1). This is
even observed in antibodies that target rapidly evolving pathogens, such as HIV-1 and influenza.
Antibodies target the viral spike, the envelope (Env) or hemagglutinin (HA), in the case of HIV-1
and flu, respectively (2, 3). In certain cases, antibodies that can neutralize a broad spectrum (>50%)
of viral variants can be achieved and these antibodies typically target certain conserved regions of
the viral spike. In the case of HIV-1, such broadly neutralizing antibodies (bnAbs) arise in∼10–20%
of chronically infected patients after about 5 years of infection. The long time frame is partly due to
the fact that the virus rapidly develops escape mutations to avoid antibody recognition (4, 5). This
results in bnAbs with high mutation frequencies.
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Several bnAb lineages have been identified that target HIV-
1 Env or flu HA and they each use different strategies during
the affinity maturation process to alter their CDRs to bind the
viral spike. In the CAP256-VRC26 bnAb lineage, a disulfide bond
was introduced within the heavy chain CDR loop 3 (HCDR3)
that rigidified and properly oriented it for binding HIV-1 Env,
thereby leading to breadth (6, 7). Rigidification of the HCDR3
was also important in the development of breadth of the CH65–
CH67 lineage against flu HA (8). In other cases, structural
changes of the paratope were not observed. Instead, there were
mutations within the CDRs that introduced residues or rotamers
of residues necessary for interacting with Env. This was observed
in the DH270 and CH235 antibody lineages where improbable
mutations were necessary in interacting with key components of
Env and/or Env glycans (9–12). Deletions and/or insertions in the
CDRs could also alter the angle of approach of antibodies with
Env, allowing them to accommodate glycans on Env, as observed
in the PGT121 bnAb lineage (13–16).
While CDRs are responsible for the majority of the direct
contacts made with an antigen, SHM does also occur in
antibodies outside of their CDRs, in the intervening framework
regions (FWRs). While the FWRs help stabilize the antigen-
binding site and define the conformations of the CDR loops,
the roles of mutations in the FWR are not well-understood.
Reports have shown that FWR mutations can be responsible
for the thermal destabilization of HIV-1 bnAbs, but not weakly
neutralizing HIV-1 antibodies (17, 18). FWRmutations have also
been shown to increase the dynamics of antibodies, leading to
neutralization breadth (17, 19, 20).
The CH103 bnAb lineage, derived from patient CH505,
produced several bnAbs including CH103, which target the CD4
receptor binding site (CD4bs) of the HIV-1 Env (21). Crystal
structures of antibody fragments from this lineage showed that
the orientation of the heavy chain variable domain (VH) changed
relative to the light chain variable domain (VL) in the transition
from intermediate antibody I3.2 to I2 during affinity maturation,
potentially through FWR mutations (22). While the CD4bs is
relatively conserved, rapid mutations in the nearby Env variable
loop 5 (V5) can lead to resistance against CD4bs antibodies
(23). In the CH505 patient, Env insertion mutations in V5
occurred throughout virus evolution, which reduced the potency
of CH103 lineage bnAb precursors through steric interference
(22). In response to these insertions, over the course of affinity
maturation the antibody VL domain shifted away from VH
and the Env V5 loop to accommodate the V5 loop insertions.
Different VL orientations relative to VH were observed in the
structures of intermediate antibody I3.2 and of the chimeric
antibody, I3.1. These antibodies both contain the VHDJH of I3,
but this is paired with either the VLJL of the unmutated common
ancestor (UCA) in I3.2 or with the VLJL of the more mature
intermediate antibody I2 in I3.1. Thus, this revealed that the shift
in VL was mainly attributed by the identity of the antibody’s
light chain.
To determine if FWR mutations, specifically ones in the
antibody light chain at the VH-VL interface, were responsible
for the shift observed in the CH103 lineage and breadth
development, we performed binding measurements to show
that these mutations improved affinity toward an autologous
(strain specific) HIV-1 Env and heterologous (different strain)
HIV-1 Env with longer V5 loops. We also determined the
crystal structure of a mutant, which shows that two residues
in the FWR at the VH-VL interface could lead to a large
part of the observed shift seen in the VLJL of the UCA
and I2 between intermediate antibodies I3.2 and I2. Thermal
melts showed that stability was not altered. Our analysis
suggests that few mutations can have a large impact on antigen
binding, and that antigen distal FWR mutations occurring
during antibody maturation can lead to the structural properties
necessary to improve affinity toward an antigen without
altering stability.
RESULTS
Antibody Interface Mutations Improve
Binding to Autologous and Heterologous
HIV-1 Envs With Longer V5 Loops
During infection of the CH505 donor, insertion mutations were
introduced in the V5 loop of the CH505 HIV-1 envelopes
as they evolved (21). While the UCA and early intermediate
antibodies had a structure whose VL domain, specifically the
antibody DE loop residues 65L-67L, would clash with V5 loops
that were longer than that of the CH505 transmitted founder
(T/F) Env, the relative shift in VL with respect to VH appeared
to accommodate these V5 loop insertions as well as the longer
V5 loops found in heterologous HIV-1 Envs (Figure 1A). As a
result, autologous CH505 Envs with longer V5 loops displayed
differential binding to different members of the CH103 antibody
lineage (i.e., they bound better to later members of the lineage
than earlier members), whereas the CH505 T/F Env bound with
similar affinity to all CH103 lineage members (Table 1) (22).
To assess the role of residues at the VH-VL interface on
binding Env, we generated an Fabmutant, “I32M”, which consists
of two interface mutations in the light chain of I3.2 (i.e., the
UCA VLJL). The light chain mutations we introduced, Q38LV
and L46LV, were based on residues found in the mature members
of the lineage (Figures 1B,C). To test binding to HIV-1 Env,
we performed biolayer interferometry (BLI) with gp120 core,
the monomeric form of the HIV-1 Env ectodomain. Because
we wanted to identify differential binding capabilities, we tested
binding to an autologous CH505 gp120 T/F core with a three-
residue “ETF” V5 loop insertion, which occurred during the
natural evolution of the virus in the CH505 patient. I32M bound
significantly better than I3.2 to this CH505 gp120 core and with a
similar KD as the chimeric antibody I3.1, which was previously
shown to have a VL shifted relative to VH (22) (Figure 2A,
Table 1), demonstrating the importance to binding of the two
mutations at the VH-VL interface, Q38LV and L46LV. The
CH505 T/F wild-type gp120 core did not bind differentially to
CH103 lineage members, as expected, nor to our mutant, I32M,
which had similar KD (Table 1). These results suggest that the
mutations we introduced did not disrupt binding to Env and
that they improve binding to autologous Envs with significantly
longer V5 loops.
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FIGURE 1 | Comparison of wild-type and mutant Fabs. (A) Superposition of the I3.2 Fab with the CH103/gp120 outer domain complex. Two orthogonal views of the
variable region of the I3.2 Fab (heavy chain VH in orange, light chain VL in red) superposed onto the variable region of the CH103 Fab (gray) in complex with the
(Continued)
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FIGURE 1 | gp120 outer domain (blue) from ZM176.66 [Protein Data Bank (PDB) ID code 4JAN]. The V5 and CD4 binding site loops of gp120 are marked. A star
indicates location of steric clash. Interface mutations introduced in this study are shown as black sticks. Image created in PyMOL. (B) Sequence alignment of the
variable light chains of I3 wild-type and mutant Fabs. Mutations analyzed in this study are highlighted in red. (*) fully conserved residue, (:) strong conservation of
properties, (.) weak conservation of properties, a blank space indicates little to no conservation of properties. (C) CH103 bnAb clonal lineage tree. The part of the
CH103 lineage under study is shown. Gray lines represent other branches in the lineage. The UCA is shown on the left, the intermediates of interest are circled, and
the CH103 bnAb has a rectangle around it. Heavy and light chain compositions are indicated with red arrows. The chimeric antibody is also defined based on its
heavy and light chain compositions.
TABLE 1 | Dissociation constants (KD, in µM) between CH103 lineage Fabs and
gp120 core variants.
CH505 T/F
gp120 core
WT
CH505 T/F
gp120 core
V5 ETF
mutant*
92UG037.8
gp120 core
WT
92UG037.8
gp120 core V5
mutant**
I3.2 1.06 ± 0.09 >100 >100 –
I32M 0.98 ± 0.06 15.51 ± 4.11 41.89 ± 8.26 –
I33M 1.86 ± 0.11 3.70 ± 0.18 16.17 ± 2.21 –
I3.1 1.98 ± 0.34 23.74 ± 2.77 3.28 ± 0.83 10.5 ± 0.5***
UCA WT 2.40 ± 0.04*** NB NB 52.23 ± 6.37
UCA Q39HL – – – 25.10 ± 2.43
UCA S56HE – – – 6.98 ± 0.44
UCA Q39HL,
S56HE
– – – 2.20 ± 0.30
*A three residue “ETF” insertion was added to the V5 loop of wild-type CH505 T/F
gp120 core.
**V5 loop residues “GNINES” of wild-type 92UG037.8 gp120 core were replaced with
“KNNT” of CH505 T/F virus Env.
***Published elsewhere (22).
NB denotes no binding detected.
Dashes indicate combinations not tested.
A hallmark of breadth is the ability of antibodies to bind and
neutralize heterologous virus strains. To determine if our I32M
mutant could also display improved binding toward heterologous
Envs, we tested binding to HIV-1 strain 92UG037.8, whose
sequence in the V5 loop differs and is two amino acids longer
than that of the CH505 T/F Env. Analysis by BLI shows that I32M
binds to this Env with a significantly smallerKD than its wild-type
counterpart I3.2, but not as well as the chimeric antibody I3.1
(Figure 2B, Table 1). These results suggest that two mutations
alone in the VH-VL interface improve binding to both autologous
and heterologous Envs with longer V5 loops, and thereby
contribute to breadth against different HIV-1 strains, however,
additional light chain mutations may further improve binding to
heterologous Envs.
Few Mutations in the UCA Can Result in
Heterologous HIV-1 Env Binding
The UCA is the ancestor of an antibody lineage that is produced
against the autologous virus that causes infection. In the UCA of
the CH103 lineage, Q39H in the heavy chain forms a reciprocal
side-chain hydrogen bond with the light chain Q38L at the VH-
VL interface (22). Moreover, the I3.2 early intermediate antibody
has 18 mutations, only in its heavy chain, when compared
to the UCA (Supplementary Figure 1). To determine whether
mutations at the VH-VL interface can improve binding to the
progenitor antibody, we introduced the Q39HL mutation in
its heavy chain and tested binding by BLI. Since the UCA of
the CH103 lineage binds with a similar affinity to the CH505
T/F gp120 core as other members of the lineage and it cannot
bind to CH505 or heterologous gp120 cores with longer V5
loops (Table 1), we tested a 92UG037.8 gp120 core whose V5
loop was replaced with a shorter one from the CH505 T/F
Env (22). While binding is fairly weak, comparison to the
binding of the wild-type UCA shows that the introduction
of this single mutation can improve binding by a factor of
two (Figure 2C, Table 1). To ensure that the rapid association
and dissociation rates observed were not due to bulk shifts at
such high gp120 core concentrations, we also tested binding
to the VRC01 bnAb, which recognizes the CD4bs but with a
different approach angle (24, 25). This bnAb displayed slower
on and off rates, distinguishing its binding kinetics from those
of CH103 lineage members and their corresponding mutants
(Supplementary Table 1, Supplementary Figure 2). This result
suggests that the disruption of the VH-VL interface Q39H-Q38L
reciprocal side-chain hydrogen bond is important in affinity
maturation and can even improve binding of the earliest antibody
lineage member.
Because binding to the UCAQ39HLmutant was still relatively
weak (KD = 25.10µM), we wanted to see if any mutations
could further significantly improve binding to the heterologous
Env. The published CH103 bnAb-gp120 structure shows that
E56H of the CH103 bnAb heavy chain HCDR2 loop engages in
hydrogen bonding contacts with the backbone of the conserved
gp120 CD4bs (21). Thus, we introduced the S56HEmutation into
the UCA Q39HL mutant and tested binding to the 92UG037.8
gp120 core V5 mutant. The UCA Q39HL, S56HE double mutant
could bind to the 92UG037.8 gp120 core V5 mutant with low
micromolar affinity (KD = 2.20µM) (Table 1). This data suggests
that while the loss of that VH-VL interface hydrogen bond is
important even for the UCA in gaining breadth against different
viruses, the contribution from CDRs is still important.
VH-VL Interface Mutations Alter Relative
Orientations of the Antibody Variable
Domains
Because Q38L and L46L of the light chain are involved in
significant interactions at the VH-VL interface and mutating
these residues improves binding to Envs, we wanted to determine
what structural changes these mutations cause. To aid in
crystallization, we added an additional mutation, Y32LN, in the
light chain of I32M to create “I33M.” Y32LN occurs during
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FIGURE 2 | Kinetic Studies by biolayer interferometry. Curves of I3.2 and I32M binding to (A) CH505 gp120 core with an “ETF” insertion in the V5 loop and (B)
92UG037.8 gp120 core. (C) Curves of the UCA and the UCA Q39HL mutant binding to 92UG037.8 gp120 core with a V5 mutation. The V5 loop of CH505 T/F Env
was grafted in the place of the V5 loop of 92UG037.8 Env. In each case, the Fab was immobilized onto an anti-human Fab-CH1 biosensor, and gp120 constructs
were introduced at three or more different concentrations, ranging from low micromolar to high micromolar, depending on the mutant tested.
affinity maturation of the CH103 lineage and N32L first appears
in the VLJL of intermediate antibody I2 (Figures 1B,C). In
later members of the lineage, N32L of the light chain CDR
loop 1 (LCDR1) was observed to hydrogen bond with the
LCDR2 and HCDR3 loops, stabilizing the conformation of
the latter and so we hypothesized the same would happen
in I33M.
We determined the crystal structure of I33M to a resolution
of 2.36 Å (Table 2) and compared it to those of the wild-
type intermediate I3.2, the CH103 bnAb, and chimeric I3.1
Fabs (Figure 3, Supplementary Figure 3). The VH of I33M was
superposed on that of the wild-type Fabs, since the VH contacts
the CD4bs on Env (Figure 1), which is invariant throughout
the evolution of the virus and thus expected to bind antibodies
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TABLE 2 | Data collection and refinement statistics.
I33M
Data collection
Space group P65
Cell dimensions
a, b, c (Å) 131.6, 131.6, 104.9
α, β, γ (◦) 90, 90, 120
Resolution (Å) 50.0–2.36 (2.40–2.36)
Total reflections 249,141
Unique reflections 42,585
Completeness (%) 99.2 (95.7)
Rmerge 12.6 (97.4)
I/σ(I) 13.0 (1.3)
Multiplicity 5.8 (5.5)
CC(1/2) 0.993 (0.504)
Refinement
Resolution (Å) 47.65–2.36
Rwork/Rfree (%) 18.5/22.3
No. atoms
Protein 6,346
Ligand/ion 13
Water 304
Ramachandran favored (%) 97
Ramachandran outliers (%) 1.3
R.M.S. deviations
Bond lengths (Å) 0.008
Bond angles (◦) 1.15
B-factors (Å2)
Protein 52.70
Ligand/ion 22.30
Water 56.00
*Values in parentheses are for highest-resolution shell.
in the same way throughout antibody affinity maturation.
Superimposed VH domains of I3.2, I33M, and I3.1 demonstrate
that I33M has a VL orientation intermediate between that of
I3.2 and I3.1 (Figures 3A–C), though it is much more similar
to that of I3.1 and to mature members of the antibody lineage
(Figure 3B, Supplementary Figure 3A). Additionally, the DE
loop of the antibody, from which residues 65L-67L clash with the
Env V5 loop in the case of I3.2 and the UCA of the lineage, is
shifted for I33M in a way that would eliminate the clash, although
it is not shifted to the same extent as I3.1 and the CH103 bnAb
(Figure 3D, Supplementary Figure 3B).
As expected, the Q38LV mutation in I33M disrupted the
reciprocal side-chain hydrogen bond interaction with Q39H,
resulting in more compact hydrophobic packing seen in the
mature CH103 lineage Fabs (Figure 4, Supplementary Figure 3).
Moreover, in the case of the UCA and I3.2, L46L is involved
in hydrophobic packing by bearing on the F100DH ring, which
is a bridge between P96H and Y49L at the domain interface.
Replacing leucine with the shorter valine at this position in I33M
causes F100DH (Y100DH in the case of the CH103 bnAb) to
swing closer to Y49L to maintain hydrophobic interactions, while
P96H appears unaffected. This is similar to what was observed in
I3.1 and the CH103 bnAb (Figure 4, Supplementary Figure 3C)
(22). Thus, Q38LV and L46LV contribute to VH-VL packing.
We further analyzed the structures to see if N32L made similar
contacts in the different antibodies despite the different extents
of orientation shifts of their VL domains relative to VH. As with
the chimeric I3.1 and mature CH103 bnAb, N32L in I33M could
form the same hydrogen bond with the HCDR3 loop, specifically
with N100BH, which is conserved in all members of the lineage
(Figure 4, Supplementary Figures 1, 3C). Of note, the distances
between the backbones of light chain residue 32 (Y32L in the case
of the early CH103-lineage members UCA and I3.2 and N32L for
later members and I33M) and heavy chain residue 100B are very
similar for the three Fabs: 6.4 Å for I33M, 6.2 Å for I3.1, and 6.4
Å for I3.2, suggesting that the Y32LNmutation does not alter the
VH-VL domain interface spacing and that the Q38LV and L46LV
mutations are the sole determinants of the observed shift.
To determine what effect Y32LN has on binding Envs, we
performed BLI with I33M and found that it bound with a
stronger affinity to the CH505 gp120 T/F core ETF mutant and
92UG037.8 wild-type gp120 core than I32M but with the same
affinity to CH505 gp120 T/F wild-type gp120 core (Table 1).
This suggests that the hydrogen bond that N32L makes with
the HCDR3 loop, which binds to the CD4bs, contributes to
Env binding.
VH-VL Interface Mutations Do Not Alter
Antibody Stability
To determine what, if any, effects the VH-VL interface mutations
and structural changes have on thermostability, we measured the
melting temperature (Tm) of the mutants we generated using
circular dichroism thermal melts (Figure 5). Tm values for our
mutants are similar and fall within the wide reported range of
Fab melting temperatures (65–90◦C) (26, 27). Comparison to
the melting temperature of I3.2 shows that the introduction of
mutations in the light chain at the VH-VL interface, or Y32LN
in the CDR, has no significant effect on thermostability. We also
determined the Tm for the CH103 bnAb. CH103 had a similar
melting temperature as I3.2, consistent with the reported value
of 65.5◦C and Tm trend determined by differential scanning
calorimetry by others (18).
DISCUSSION
HIV-1 bnAbs that evolve naturally in infected individuals have
high levels of mutations in the CDRs and FWR. While many
mutations in the CDR can impact binding to antigen, the roles
of the FWR mutations are usually less clear. It has been shown
that FWR mutations can be important for the development of
breadth (18, 28). In this study, we identified two FWR residues at
the VH-VL interface, Q38LV and L46LV, that were important for
improving binding to HIV-1 Envs with longer V5 loops. These
two mutations alone were sufficient for the significant shift of the
orientation of the VL domain with respect to VH over the course
of affinity maturation of the CH103 bnAb lineage. Moreover,
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FIGURE 3 | Superpositions of I3.2, I33M, and chimeric I3.1. (A) Overall superposition of mutant Fab I33M onto I3.2. The domains are colored: I33M VH (yellow) and
VL (green), and I3.2 VH (orange) and VL (red). (B) Overall superposition of mutant Fab I33M onto I3.1. The domains are colored: I33M VH (yellow) and VL (green), and
I3.1 VH (blue) and VL (cyan). (C) Overall superposition of mutant Fab I33M onto I3.2 and I3.1. Domains are colored as in panels (A,B). The constant domains are not
shown for clarity. Relative shifts are indicated with a cyan arrow. The black arrow shows the shift in the antibody DE loop. (D) Zoomed in view of the DE loops of I3.2
(red), I33M (green), and I3.1 (cyan).
these mutations did not alter the stability of the antibodies
consistent with reports elsewhere (18).
Q38LV, distal to the Env binding site, eliminates hydrogen
bonding with Q39H. Moreover, the Q39HL heavy chain mutation
first appeared in I2 of the lineage and so I3.2 has a Q39H
(Supplementary Figure 1). Our structure of I33M shows that
a relative shift in orientation of the domains can occur in
the absence of the Q39HL mutation, since this mutant only
consisted of light chain mutations in I3.2 (Figure 4). Moreover,
mutation of just one of these residues alone, which disrupts
the variable interface hydrogen bond, is sufficient for improving
binding to a heterologous HIV-1 Env (Figure 2C, Table 1), an
important feature in the development of breadth. L46LV, also
within the VH-VL interface, alters hydrophobic packing. Thus,
the mutations Q38LV and L46LV in the antibody light chain
brought the relative orientation of the VH and VL domains of the
antibodies closer to that of the mature members of the CH103
lineage to accommodate Envs with larger V5 loops. Of note, the
I32M double mutant bound to the CH505 gp120 core “ETF” V5
loop mutant with a similar dissociation constant (Table 1) as a
later intermediate, I2 (22) and the chimeric I3.1. This suggests
that all the mutations accrued in late CH103 lineage members
may not be necessary for antibody affinity maturation, at least
against autologous Envs. These results further demonstrate
that it is important to consider more than just the CDRs for
vaccine design.
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FIGURE 4 | VH-VL interface residues and their effects. Zoomed in views of residues that were mutated are shown as sticks for the three Fabs. Domains for the different
Fabs are colored as follows: I33M VH (yellow) and VL (green), I3.2 VH (orange) and VL (red), and I3.1 VH (blue) and VL (cyan). Hydrogen bond distances are given.
Our work did also identify a few critical CDR mutations that
occurred throughout affinity maturation that greatly improved
antibody binding to Env. A significant improvement in KD was
observed when we introduced the S56HE mutation into the
wild-type UCA (∼7-fold) or the UCA Q39HL mutant (∼3-fold;
Table 1). Another example of a single CDR mutation enhancing
affinity was demonstrated by our I33M mutant, which had the
Y32LN mutation in the LCDR1. The I33M mutant bound to the
92UG037.8 gp120 core with a ∼3-fold lower KD than that of
I32M (Table 1). A likely consequence of the Y32LN mutation in
the LCDR1 of I33M and other mature CH103-lineage members
is the stabilization of the configuration of the HCDR3 loop,
important for contacting the conserved CD4bs of the CH505
HIV-1 Env. The HCDR3 loop was disordered in the UCA, but
not in later members of the CH103 lineage (22). The hydrogen
bonding we observed in I33M between N32L and N100BH
(Figure 4) is reminiscent of what is observed in I2 and the
bnAbs from this lineage. This illustrates that very few mutations
were necessary for the correct configuration of the HCDR3 loop.
While FWR mutations have been shown to increase antibody
flexibility in some cases (17, 28), results from our crystal structure
are consistent with more standard trends observed, i.e., that
affinity maturation results in a more rigid antibody structure,
specifically in the HCDR3 loop (8, 29–33).
In the CH103 lineage, a significant increase in both
heterologous binding and heterologous neutralization was
observed during the transition from I3.2 to I2, without much
change thereafter (21). Additionally, a shift in the orientation
of the VL domain relative to that of the VH was also observed
between these two antibodies, and the CH103 bnAb had a similar
VL orientation as I2 and the chimeric I3.1 with respect to VH
(22). Furthermore, it was shown through structures and binding
data, that CH103-lineage Fabs whose VL domain had shifted
relative to the VH domain had higher binding affinity toward
HIV Envs with longer V5 loops than antibodies from the lineage
in which this shift had not yet occurred. Because many other
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FIGURE 5 | Melting temperatures of Fabs. Tm’s of various Fabs and mutants are shown. Standard deviations are from three or more replicates.
HIV Envs tend to have V5 loops that are longer than that of the
CH505 T/F, this suggests there may be a correlation between a
shift in VL and heterologous neutralization breadth in the case
of the CH103 lineage. Since our I3.2 mutant also had a shift in
VL, we expect that I32M and I33M have broader neutralization
capabilities than the wild-type I3.2, though this has yet to be
confirmed experimentally.
A challenge in eliciting antibodies with great breadth via
HIV-1 vaccination is the fact that bnAbs take years to develop,
requiring highmutation frequencies. Thus, a deep understanding
of antibody affinity maturation, paired with virus evolution, is
needed to determine key steps in these processes and to identify
which stages to target by vaccination. The relative shift in the VH
and VL domains was demonstrated to be important and here we
show that very few mutations in the antibody variable domain
interface are necessary for this structural change. Thus, exposure
to an antigen that would lead to such a shift may lead to a more
rapid antibody response than one in which many mutations in
the antigen combining site are necessary. Our results also have
implications for the design of therapeutic antibodies. Alterations
at the VH-VL interface can alter the antigen-combining site in a
favorable way to lead to more potent and broad antibodies.
Complex evolutionary trajectories are followed in different
HIV-1 bnAb lineages, therefore, structural analyses at multiple
time points during the maturation pathway could reveal new
phenomena. Since the shift in orientation of VL relative to VH
that we observed in our mutant is similar to but not exactly the
same as that observed in the mature CH103 lineage members,
there may be additional mutations that would result in a greater
shift and should be explored. By comparing available structures
of the wild-type, chimeric, and mutant antibodies (22), we find
that there are no other mutations in the antibody light chain at
the VH-VL interface that change identity, rotamers, or amino
acid binding partners throughout affinity maturation of this
particular lineage. Thus, it is possible that there are mutations
in other regions of the FWR or in the CDRs that affect the shift
in VL relative to VH. Additionally, a high-resolution structure
of the CH103 UCA in complex with an Env has not yet been
determined. Such a structure is necessary to better understand
antibody-virus co-evolution in this lineage as well as properties
of HIV-1 Env that triggered the lineage. While the CH103 UCA
can only bind the CH505 T/F Env, it binds poorly to an Env
stabilized in a closed conformation (data not shown). Our work
shows that introducing the S56HE mutation in the UCA HCDR2
loop alone significantly improves its binding to a heterologous
Env (Table 1). This provides a means for determining an atomic
resolution structure of the UCA with Env to provide greater
insights for HIV-1 vaccine development.
MATERIALS AND METHODS
Expression and Purification of Fabs
Site-directed mutagenesis was performed using manufacturer’s
protocols (Stratagene) to introduce mutations into the UCA
heavy and light chains. Fabs were expressed in HEK293F
suspension adapted cells via transient transfection using linear
polyethylenimine (PEI) following the manufacturer’s suggested
protocol. For 200mL of suspension cell culture, 100 µg of total
plasmid was used. After 5 days of expression, the supernatant
was clarified by centrifugation. Each His-tagged CH103-lineage
Fab was loaded onto Ni-NTA superflow resin (Qiagen) pre-
equilibrated with Buffer A (10mM Tris, pH 7.5, 200mM NaCl),
washed with Buffer A then Buffer A + 10mM imidazole, and
finally, eluted with Buffer A + 350mM imidazole. Each Fab
was then purified by gel filtration chromatography using a
SuperdexTM 200 Increase 10/300 GL column (GE Healthcare) in
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buffer of 10mM Tris, pH 7.5, 100mMNaCl. Fractions of interest
were further concentrated.
Plasmids containing the CMVR VRC01 Ig heavy and light
chains were obtained from the NIH Aids Reagents Program.
The protein was expressed in 293F cells as described for
Fabs above. The clarified supernatant was diluted twofold
using 1× PBS buffer and purified using protein A agarose
resin (Pierce), according to manufacturer’s protocols. The
eluent was concentrated and further purified by gel filtration
chromatography in buffer of 10mM Tris, pH 7.5, 100mM
NaCl using a SuperdexTM 200 Increase 10/300 GL column
(GE Healthcare). The VRC01 Fab was obtained by digesting
the Ig using papain (Pierce) and by running the digested
products through protein A resin (Pierce) according to
manufacturer’s protocol. The Fab was then purified by gel
filtration chromatography again as described above.
Expression and Purification of HIV-1 Env
gp120s
The codon-optimized synthetic constructs of the CH505 T/F
HIV-1 subtype C gp120 containing amino acid (a.a.) 41–492
(HXB2 numbering) 1V123 (core) was described previously (22).
Briefly, the same pVRC-8400 expression vector as described
for Fabs was used and the construct contained an N-terminal
6×-histidine tag. The expression construct also contained a
leader sequence encoding the tissue plasminogen activator signal
sequence. The IRES-puro vector containing 92UG037.8 HIV-1
subtype A gp120 a.a. residues 1–492 (HXB2 numbering) 1V123
(core) with a 6×-histidine tag inserted between residues 40
and 41 and V5 mutations was also described previously (22).
Recombinant Env glycoproteins were expressed in HEK 293T
cells and purified as described for His-tagged Fabs.
Bio-layer Interferometry
Kinetic measurements of Fab binding to HIV-1 Env gp120 cores
were carried out using the fortéBIO BLItz instrument using
the same buffer all of our proteins were purified in (10mM
Tris, pH 7.5, 100mM NaCl) to minimize bulk shift effects. Fabs
at concentration 0.2 mg/mL were immobilized on Dip and
ReadTM Anti-Human Fab-CH1 second Generation Biosensors
until saturation was reached (3min). Env constructs were tested
at concentrations ranging from 9.6 to 110µM, depending on the
particular construct used and its solubility, as well as based on
its binding affinity to each Fab tested. The CH505 T/F gp120
wild-type core was tested at concentrations of 6.8, 22.0, and
66.0µM, the CH505 T/F gp120 core ETF mutant was tested
at concentrations 9.6, 19.3, and 58.0µM, the 92UG037.8 gp120
core was tested at concentrations 10.8, 27, and 54.0µM, and the
92UG037.8 gp120 core V5 mutant was tested at concentrations
27.5, 55.0, and 110.0µM. Association and dissociation were
each monitored for 2–2.5min. Step corrections, at the start
of association and at the start of dissociation, were performed
manually using Microsoft Excel. Analyses were then performed
using a global fit of at least three measurements using nonlinear
regression curve fitting using the Graphpad Prism software,
version 8.
Circular Dichroism
CD spectra were recorded over the range of 260–210 nm to
confirm the presence of a β-sheet signal at 216 nm (34) using an
AVIV Model 435 Circular Dichroism Spectrometer. Fabs were
loaded into 700 µL quartz crystal cuvettes at a concentration
of 0.02 mg/mL in PBS buffer. Thermal melts were done from
20 to 90◦C. CD signals at 216 nm were monitored every 0.5◦C
as the temperature of the samples increased at a ramp rate of
0.5◦C/min. The samples were allowed to equilibrate for 5 s at each
temperature before CD signals were recorded at an averaging
time of 15 s. Data was analyzed with OriginLab using signal
smoothing and assuming a two-state model with constant 1H
(35). In order to obtain the best fits, the approximated starting
and ending baselines (which were assumed to be linear), melting
temperature, and enthalpy of unfolding were adjusted. Curves
were fit to a chi-squared tolerance value of 1× 10−9.
Crystallization of CH103 Lineage Fab
Mutants
I33M was concentrated to 11.24 mg/mL prior to crystallization.
I33M crystallized in 96-well-tray format, set up with a
TTPLabTech Mosquito R© HTS in 1.5M AmSO4, 100mMHepes,
pH 7.0, 5% PEG 400 and was optimized in 24-well-format in
which the pH of the solution was adjusted to 7.23.
Data Collection, Structure Determination,
and Refinement
X-ray diffraction data was collected using beamlines at the
Advanced Photon Source at Argonne National Laboratory. I33M
data were collected at beam line 24-ID-E using a 0.98 Å
wavelength. Data set from an individual crystal was processed
with HKL2000 (36). Molecular replacement calculations for the
Fab were carried out with PHASER (37) using published I3.2
[Protein Data Bank (PDB) ID 4QHL] as the search model. The
Fab was broken up into the variable and constant domains in
order to perform two separate searches. I33M contained two
molecules in the asymmetric subunit.
Refinement was carried out with PHENIX (38), and all model
modifications were carried out with Coot (39) and PyMOL.
During refinement, maps were generated from combinations of
positional, group B-factor, and TLS (translation/libration/screw)
refinement algorithms. All refinements used secondary structure
and NCS restraints. Structure validations were performed
periodically during refinement using the MolProbity server (40).
The final refinement statistics are summarized in Table 2.
Protein Structure Analysis and Graphical
Representations
The structures analyzed in this study were superposed by least
squares fitting in Coot.
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